Public release date: 26-Jul-2012 [ | E-mail | Share ] <\/p>\n
Contact: Vicki Cohn vcohn@liebertpub.com<\/a> 914-740-2100 x2156 Mary Ann Liebert, Inc.\/Genetic Engineering News<\/p>\n New Rochelle, NY, July 26, 2012 Administering high-doses of interleukin-2 (IL-2) has been the preferred treatment for patients with stage IV metastatic melanoma. An article published in the current issue of Cancer Biotherapy and Radiopharmaceuticals, a peer-reviewed journal from Mary Ann Liebert, Inc. (http:\/\/www.liebertpub.com<\/a>), explores whether or not this regimen is still the most effective. The article is available free online at the Cancer Biotherapy and Radiopharmaceuticals website (http:\/\/www.liebertpub.com\/cbr<\/a>). <\/p>\n In the article \"Should High-Dose Interleukin-2 Still Be the Preferred Treatment for Patients with Metastatic Melanoma?\" (http:\/\/online.liebertpub.com\/doi\/full\/10.1089\/cbr.2012.1220<\/a>) Robert Dillman and colleagues at the Hoag Institute for Research and Education and Hoag Family Cancer Institute, Newport Beach, CA concluded that until long-term survival data for some of the newer drugs are available, patients with stage IV metastatic melanoma who are well enough to be given intensive IL-2 therapy should receive it initially, either alone or in combination with one of the newer therapeutic agents. <\/p>\n \"This is an important article that puts into perspective the reasons why IL-2 should continue to be the initial therapy in patients with metastatic melanoma,\" says Editor Donald J. Buchsbaum, PhD, Division of Radiation Biology, Department of Radiation Oncology, University of Alabama at Birmingham. <\/p>\n ### <\/p>\n About the Journal <\/p>\n Cancer Biotherapy and Radiopharmaceuticals (http:\/\/www.liebertpub.com\/cbr<\/a>), published 10 times a year in print and online, is under the editorial leadership of Editors Donald J. Buchsbaum, PhD and Robert K. Oldham, MD, Lower Keys Cancer Center, Key West, FL. Cancer Biotherapy and Radiopharmaceuticals is the only journal with a specific focus on cancer biotherapy, including monoclonal antibodies, cytokine therapy, cancer gene therapy, cell-based therapies, and other forms of immunotherapy. The Journal includes extensive reporting on advancements in radioimmunotherapy and the use of radiopharmaceuticals and radiolabeled peptides for the development of new cancer treatments. Topics include antibody drug conjugates, fusion toxins and immunotoxins, nanoparticle therapy, vascular therapy, and inhibitors of proliferation signaling pathways. <\/p>\n About the Publisher <\/p>\n Mary Ann Liebert, Inc., publishers (http:\/\/www.liebertpub.com<\/a>) is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Journal of Interferon & Cytokine Research, Human Gene Therapy and Human Gene Therapy Methods, and Stem Cells and Development. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 70 journals, books, and newsmagazines is available at Mary Ann Liebert, Inc. (http:\/\/www.liebertpub.com<\/a>) <\/p>\n<\/p>\n More here: <\/p>\n Should high-dose interleukin-2 continue to be the treatment of choice for metastatic melanoma?<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" Public release date: 26-Jul-2012 [ | E-mail | Share ] Contact: Vicki Cohn vcohn@liebertpub.com<\/a> 914-740-2100 x2156 Mary Ann Liebert, Inc.\/Genetic Engineering News New Rochelle, NY, July 26, 2012 Administering high-doses of interleukin-2 (IL-2) has been the preferred treatment for patients with stage IV metastatic melanoma. An article published in the current issue of Cancer Biotherapy and Radiopharmaceuticals, a peer-reviewed journal from Mary Ann Liebert, Inc. (http:\/\/www.liebertpub.com<\/a>), explores whether or not this regimen is still the most effective. Continue reading